ALS treatment pipeline, worth a read highlighted some key points below:
I have considered that the high rate of ALS treatment failures is due to the sporadic nature of ALS. Therefore, for a treatment to succeed it would need to be selectivity without off-target side effects. We know Monepantel has a high safety profile. Also the most recent HEALY platform regimens are both focused on TDP43 inhibition. Take this as a sign that the specialists agree this is an area of focus.
This bodes well for Monepantel, as an activator of Autophagy (natural cleansing process for protein aggregation), mTor inhibition (anti-inflammatory) and its downstream target (preventing TDP-43 aggregation along with other proteins linked to ALS).
Also, as highlighted by Pharmaust and many here, Monepantel has the potential to translate to other neurodegenerative disorders. Preclinicals inbound - Watch this Space!
Selective ALS Targets
Lots of downstream targets but TDP43, mtor and autophagy closer to the top of the list - interesting how does this sit with Monepantal?
READ ME - ALS PIPELINE!
Source: 14728214.2024.2333420 (tandfonline.com)
Healy Platform Trials (status)
Source:
1Study Drugs in the HEALEY ALS Platform Trial (massgeneral.org)2Zilucoplan Arm in HEALEY Trial for ALS Stopped Early for Lack of Benefit (alsnewstoday.com)3Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial) (prnewswire.com)4Healey & AMG Center announces top line results in ALS platform trial with CMN-Au8 (massgeneral.org)5Phase 3 clinical trial of pridopidine in ALS patients likely this year (alsnewstoday.com)
- Forums
- ASX - By Stock
- PAA
- Ann: PharmAust Presentation
Ann: PharmAust Presentation, page-82
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 376984 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 25091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 366984 | 0.170 |
7 | 256513 | 0.165 |
9 | 399304 | 0.160 |
6 | 336734 | 0.155 |
8 | 227993 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 252275 | 4 |
0.185 | 367471 | 6 |
0.190 | 820111 | 8 |
0.195 | 593409 | 10 |
0.200 | 302726 | 11 |
Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online